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Abstract. Over the years several studies have demonstrated the abil-
ity to identify potential drug-drug interactions via data mining from
the literature (MEDLINE), electronic health records, public databases
(Drugbank), etc. While each one of these approaches is properly statisti-
cally validated, they do not take into consideration the overlap between
them as one of their decision making variables. In this paper we present
LInked Drug-Drug Interactions (LIDDI), a public nanopublication-based
RDF dataset with trusty URIs that encompasses some of the most cited
prediction methods and sources to provide researchers a resource for
leveraging the work of others into their prediction methods. As one of
the main issues to overcome the usage of external resources is their map-
pings between drug names and identifiers used, we also provide the set
of mappings we curated to be able to compare the multiple sources we
aggregate in our dataset.
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1 Introduction
Studies analyzing costs over time have shown that adverse drug reactions (ADRs)
cost over $136 billion a year [13]. One significant cause of ADRs are drug-drug
interactions (DDIs) which greatly affect older adults due to the multiple drugs
they are taking [3]. A DDI occurs when the effect of any given drug is altered by
another drug which results in an unpredictable effect. While new drugs, before
market approval, are tested in both in vivo and in vitro methods [19], it is unfea-
sible to test their interactions with all other approved and experimental drugs.
In the recent years, computational approaches have been trying to infer potential
DDI signals using a wide variety of sources [6,9,16,17], however these methods
produce thousands of statistically plausible predictions [6,8], thus making the
task of testing them in an experimental setting impractical.
We are therefore facing the need of combining data from various disparate
sources, but at the same time have to remain aware of their provenance due
Fig. 1. Overview of the Linked Drug-Drug Interactions dataset and the data sources
that it incorporates and their original formats
to differences in individual quality and overall confidence. Depending on their
primary source and their provenance path, two data entries about the same
DDI might substantially increase our confidence about a relation. By relying on
Semantic Web technologies such as RDF – and more specifically nanopublica-
tions [7] – these provenance paths can be represented in an explicit and uniform
manner. In this paper we introduce LInked Drug-Drug Interactions (LIDDI), a
dataset that consolidates multiple data sources in one cohesive linked place that
allows researchers to have immediate access to multiple collections of DDI pre-
dictions from public databases and reports, biomedical literature, and methods
that take different and sometimes more comprehensive approaches.
With great potential for use in drug safety studies, LIDDI provides the link-
ing components to branch from DDIs into individual properties of each drug
via Drugbank and UMLS, as well as mappings to other types of biomedical on-
tologies which are used to describe drug-drug interactions. In terms of direct
applications, the resources in our dataset allow researchers to quickly determine
if there is support by other DDI sources for their own predictions, allowing them
to evaluate them via consensus rather than only by independent statistical mea-
sures (AUROC values, odds ratios, etc). LIDDI offers all the mappings needed to
bridge the incorporated resources into a single comparable entity, providing extra
value for researchers looking to bridge the data sources we have connected, for
example Drugbank drug identifiers to UMLS Concept Unique Identifiers (CUI)
to Medical Subject Headings (MeSH) codes, opening endless possibilities for
reuse.
To our knowledge, this is the first public dataset exemplifying the use of
nanopublications for the integration of knowledge from multiple diverse data
sources in the field of drug safety surveillance. We believe it will facilitate cross-
referencing of results between different domains not previously available, as well
as the enrichment of drugs involved in the DDIs thanks to the linkages provided.
2 Methods
2.1 Nanopublications with Trusty URIs
Nanopublications [7] are a concept to use Semantic Web techniques (most im-
portantly RDF and named graphs) to closely link data to their provenance and
meta-data in a uniform manner. The vision is that small data packages should
become the primary format for research outputs instead of narrative articles
[15]. Technically, a nanopublication consists of an assertion graph with triples
expressing an atomic statement (about drug-drug interactions in our case), a
provenance graph that reports how this assertion came about (e.g. where it was
extracted from or what mechanism was used to derive it), and a publication
information graph that provides meta-data for the nanopublication (such as its
creators and a timestamp).
Trusty URIs [11,12] are a recent proposal to make URI links for digital arti-
facts verifiable, immutable, and permanent. Such URI identifiers contain a cryp-
tographic hash value calculated on the content of the represented digital artifact
— i.e. RDF content of nanopublications in our case — in a format-independent
way. With trusty URIs, any reference to an artifact thereby comes with the pos-
sibility to verify with 100% confidence that a retrieved file really represents the
correct and original state of that resource.
2.2 Data Schema
We represent DDIs in the following way: We instantiate the DDI class from the
Semantic science Integrated Ontology (SIO) [5]. We define a vocabulary in our
own namespace, as is normally done with Bio2RDF [4], to assign domain-specific
predicates to point from the DDI to each drug, and to the clinically-relevant event
resulting from the drug interaction. This assertion is stored in the assertion graph
of the nanopublication. We also create nanopublications to capture the mappings
between each drug and our seven sources. We use BioPortal PURL identifiers
for UMLS URIs. We use the PROV ontology [14] to capture the provenance of
each DDI by linking the assertion graph URI to a PROV activity. This activity
is linked to the software used to generate the drug and event mappings, as well
as to the citation for the method, the generation time, and the dataset where the
DDIs were extracted from. In this last case we also provide a direct link to the
original dataset used. Figure 2 highlights our general schema with a particular
example for a DDI that contains a drug-drug set.
Fig. 2. Dataset Schema shows two types of nanopublications included in the dataset.
The first captures the DDI, and the second captures drug mappings.A third one not
show captures the event mappings.
3 Data sources aggregated
In this section we provide details about the transformations we performed on
each of the data sources to be able to normalize them and use them together.
Due to space constraints we provide a very high-level view of how each source
procures and generates its data as this lies out of the scope of this dataset
paper. All the mappings provided within our dataset for UMLS concept unique
identifiers (CUI), RxNORM codes, MeSH codes and Drugbank identifiers, were
done as an initial step once we acquired all our sources.
Electronic Health Records (EHR). In [9] the authors used Stanford Translational
Research Integrated Database Environment (STRIDE) dataset comprising 9 mil-
lion unstructured clinical notes corresponding to 1 million patients that span a
period of 18 years (1994–2011) to mine DDIs from the EHR. Published as a
comma delimited file in the supplemental materials, we use the highest confi-
dence predictions as the initial basis of our dataset in terms of drugs (345) and
events (10). This dataset provides drug-drug-event sets of UMLS concept unique
identifiers (CUI), drug/event names in string literals.
FDA Adverse Event Reporting System (FAERS). We analyzed over 3.2 million
reports found on the FDA Adverse Event Reporting System (FAERS), since
there are no established algorithmic ways of determining the statistical signif-
icance of a drug-drug interaction from FAERS reports without any additional
external information, we set a threshold of each DDI to have at least ten appear-
ances in different FAERS reports for it to appear on our dataset. In this data
source, the drugs are given in string literals that normalized to RxNorm drug
names and the events normalized to MeDRA.
DrugBank. We used the RDF versions of Drugbank [18] made publicly available
through Bio2RDF. The used version was dated as 2013-07-25. We proceeded
to strip the Drugbank identifiers and their labels into string literals mapped
Fig. 3. Text-tagging pipeline. We build a term/concept dictionary from ontologies in
UMLS. We then proceed to tag concepts found in any piece of text from any source
via Unitex, resulting in a bag of UMLS CUIs for each input.
into RxNorm/SNOMED string literals. In order to extract DDIs we used the
drugbank vocabulary:Drug-Drug-Interaction type to match interacting drugs, we
then used the rdfs:label to extracted the event by concept tagging the indication
section with a modified version of the NCBO annotator used in [9]. This concept
tagging process is described on Figure 3.
Drugs.com. In order to mine DDIs from this resource, we used a web-crawling
agent developed in Python. We programmatically checked the individual drugs.com
page for each of the 345 drugs in our set and extracted all their interacting drugs.
For each of the interacting drugs we build the event part of our DDI and by an-
notating the complementary free-text section, the same way as on Figure 3,
which describes the interaction (similar to the Drugbank indication).
MEDLINE. In order to find potential DDIs signals in the biomedical literature,
we have adapted a clever method developed by Avilach et al. [1], that allows
for the use of a query with certain MeSH terms and qualifiers to find adverse
events in the literature. We modified this query by adding a MeSH term for
”Drug interactions” and modified the search to allow for two drugs instead of
one from the original approach. These modifications of the method with some
manipulation produces drug-drug-event sets.
TWOSIDES. Provided as a download by Tatonetti et al. [16], TWOSIDES con-
tains polypharmacy side effects for pairs of drugs. Mined from FDAs FAERS,
this methods is designed to complement modern signal detection approaches,
providing stratification, dampening or removing the effect of co-variates, with-
out needing to divide drug-exposed reports into strata. This resource is available
in a CSV format and features drugs in RxNorm normalized string literal form
and events in UMLS CUI form.
INferring Drug Interactions (INDI). Currently available on a website for check-
ing drug-drug interactions and provided to us by the authors [6] in a comma
separated file. This prediction method infers both pharmacodynamic and phar-
macokinetic interactions based on their similarity to existing known adverse
events that result from a common metabolizing enzyme (CYP). The provided
resources consisted of drug-drug sets (no events) in UMLS CUI form.
Table 1. LIDDI DDI event distribution between sources
Event Name EHR MEDLINE Drugbank Drugs.com FAERS TWOSIDES INDI* Protocol*
Arrhythmia 700 68 286 3,148 100 4,632 NA* NA*
Bradycardia 254 88 408 4,896 194 4,824 NA* NA*
Hyperkalaemia 1,888 42 422 4,248 146 3,840 NA* NA*
Hypoglycaemia 1,460 386 796 6,214 104 5,150 NA* NA*
Long QT syndrome 14 270 334 3,510 2 0 NA* NA*
Neutropenia 4,608 192 402 4,218 616 3,702 NA* NA*
Pancytopenia 1,880 4 270 3,146 148 5,440 NA* NA*
Parkinsonism 144 0 566 5,978 70 884 NA* NA*
Rhabdomyolysis 122 198 392 3,842 214 3,264 NA* NA*
Serotonin syndrome 896 0 384 3,960 122 1,094 NA* NA*
Total: 11,966 1,248 4,260 43,160 1,716 32,830 8,370 224
Similarity-based Modeling Protocol (Protocol). Provided to us by the authors,
Vilar et al. [17], this protocol integrates a gold standard of DDIs with drug sim-
ilarity information extracted from sources like: 2D and 3D molecular structure,
interaction profile, target similarities, and side-effect similarities. This method
generates drug interaction candidates that are traceable to pharmacological or
clinical effects. We were provided with the resulting drug-drug (no events) sets
with Drugbank identifiers.
4 Statistics and Access
Table 1 shows the total number of DDIs found with support in each of the
multiple sources we integrated. Note that these are not unique DDIs in the
sense that we have a drug1-drug2-event set that is equivalent to drug2-drug1-
event set as the directionality does not matter, thus counting them twice. We left
this reflexive drug drug interactions in our dataset to conform to the standard
employed by bio2RDF’s DrugBank repository, in order to not limit the discovery
of any potential interaction when a query is performed on any given single drug.
The dataset in its entirety contains a total of 98,085 nanopublications out of
which 345 are used for drug mappings, 10 for event mappings and the remainder
for DDIs extracted from the data sources we used. The dataset has a total of
392,340 graphs (four per nanopublications) and 2,051,959 triples, taking 723 MB
in nquads representation.
LIDDI can be accessed as a bulk download via figShare [2] and SPARQL
endpoint at: http://http://liddi.stanford.edu:8890/sparql.The dataset is also
made available via the recently installed nanopublication server network [10].
The command ‘np’ from the Java nanopublication library1 can be used to down-
load the dataset [20]:
$ np get -c -o out.trig RA7SuQ0e661LJdKpt5EOS2DKykf1ht9LFmNaZtFSDMrXg
1 https://github.com/Nanopublication/nanopub-java
5 Potential for applications and future work
The first application that this dataset has been used for involves ranking DDI
predictions from EHR data. By taking the EHR data source published by [9]
and using this resource, researchers are ranking predictions in order to deter-
mine which ones are more feasible for experimental evaluation. By leveraging
such diverse resources, the researchers have been able to use the data sources as
voting mechanisms for certain DDIs to be prioritized over others. Similar stud-
ies can be performed to determine the priority of the other data sources and
their predictions just using LIDDI and selecting a different resource to evaluate.
The authors of each data source could enhance their own predictions by using
their method and consider other sources we compiled in this dataset as gold-
standards or at least ’silver-standards’ as there is no de facto community-wide
gold standard for drug safety when it comes to drug-drug interactions. Multi-
ple applications can revolve around enhancing the DDIs listed here by enriching
the drugs and events with properties available in the Drugbank, RxNorm and
MeSH linked graphs that are not easily accessible via traditional means. This
might lead to even further linkage of other resources tying all things back to a
described DDI and helping to further explain its reason and impact. As more
researchers become aware of this resource they should be encouraged to con-
tribute to it by adding their own DDI predictions, thus enhancing the overall
availability of DDI predictions sets for scientific comparisons. We will continue
to contact authors and map their data sets into LIDDI to have a more diverse
and rich set of resources. We also plan at some point incorporate more drugs
and more events into the resource as they become available for it to have a wider
coverage of the current drug space.
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